# US 2010/0137204 A1 · Glp-1 pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137204 A1
- Document ID: US20100137204A1
- Status: Published application
- Kind: A1
- Application number: 12/448,631
- Filed: 2007-12-31
- Published: 2010-06-03
- Earliest claimed: 2006-12-29
- Inventors: Zheng Xin Dong; Roland Cherif-Cheikh; Jose-Antonio Cordero-Rigol; Resurreccion Alloza Miravete; Frederic Lacombe; Maria Dolores Tobalina Maestre
- Web page: https://patentgrep.com/patent/US20100137204A1

## CPC

- A61K 35/26: Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.

## Claims

### Claim 1

A pharmaceutical composition comprising an analog of GLP-1 prepared with a pharmaceutically acceptable salt of said analog or a mixture of the salt of said analog and the analog, thereby providing a molar ratio of analog salt to peptide analog in said pharmaceutical composition, wherein the molar ratio can be adjusted to modulate the solubility, the pH, and release effect on in vivo release profile of the peptide in said pharmaceutical composition.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said GLP-1 analog is [Aib8,35]hGLP-1(7-36)NH2.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, further comprising a divalent metal and/or divalent metal salt.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein said selected divalent metal is zinc or copper.

### Claim 5 (depends on 3)

The pharmaceutical composition according to claim 3, wherein said composition contains divalent metal salts selected from the group consisting of CuAc2, CuCl2, ZnAc2, and/or ZnCl2.

### Claim 6 (depends on 2, 5)

The pharmaceutical composition according to claim 2 or 5, wherein said salt of [Aib8,35]hGLP-1(7-36)NH2 is a pharmaceutically acceptable salt of an organic acid.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, wherein said organic acid is selected from the group consisting of acetic, trifluoroacetic, lactic, malic, ascorbic, succinic, benzoic, citric, methanesulphonic and toluenesulphonic acids.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, wherein said acid is acetic acid.

### Claim 9 (depends on 2, 5)

The pharmaceutical composition according to claim 2 or 5, wherein said salt of [Aib8,35]hGLP-1(7-36)NH2 is a pharmaceutically acceptable salt of an inorganic acid.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein said inorganic acid is selected from the group consisting of hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acids.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein said acid is hydrochloric acid.

### Claim 12 (depends on 3)

A pharmaceutical composition according to claim 3, wherein the molar ratio ranges of said [Aib8,35]hGLP-1(7-36)NH2 salt to GLP-1 peptide analog is approximately 0.5:1 to approximately 10:1.

### Claim 13 (depends on 3)

A pharmaceutical composition according to claim 3, wherein the molar ratio of said [Aib8,35]hGLP-1(7-36)NH2 salt to said divalent metal and/or divalent metal salt in said pharmaceutical composition ranges from approximately 6:1 to approximately 1:1.

### Claim 14 (depends on 13)

A pharmaceutical composition according to claim 13, molar ratio of said [Aib8,35]hGLP-1(7-36)NH2 salt to said divalent metal and/or divalent metal salt in said pharmaceutical composition ranges from approximately 5.4:1 to approximately 1.5:1.

### Claim 15 (depends on 14)

The pharmaceutical composition according to claim 14, wherein said pharmaceutically acceptable salt is [Aib8,35]hGLP-1(7-36)NH2.HCl.Zn.

### Claim 16 (depends on 14)

The pharmaceutical composition according to claim 14, wherein said pharmaceutically acceptable salt is [Aib8,35]hGLP-1(7-36)NH2.acetate.Zn.

### Claim 17 (depends on 14)

The pharmaceutical composition according to claim 14, wherein said pharmaceutically acceptable salt is [Aib8,35]hGLP-1(7-36)NH2.HCl.copper.
